Exposure–Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma-Reference-Cited by-同舟云学术

Exposure–Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma

Published:2010-05-26 Issue:1 Volume:88 Page:115-119
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:
Short-container-title:Clin Pharmacol Ther

Author:

Jang S H,Colangelo P M,Gobburu J V S

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference18 articles.

1. Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients

2. Randomized Placebo‐Controlled Trial of Fluconazole Prophylaxis for Neutropenic Cancer Patients: Benefit Based on Purpose and Intensity of Cytotoxic Therapy

3. Posaconazole: clinical pharmacology and potential for management of fungal infections

4. Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease

5. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia

Cited by 213 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approaches for posaconazole therapeutic drug monitoring and their clinical benefits;European Journal of Clinical Pharmacology;2024-09-09

2. Posaconazole gastro-resistant tablets for preventing invasive fungal disease after haematopoietic stem cell transplantation: a propensity-matched cohort study;Clinical Microbiology and Infection;2024-07

3. An Update on Breakthrough Invasive Mold Infections;Mycopathologia;2024-06-13

4. Clinical Pharmacology Strategy for Registration in Japan with a Case Example of Posaconazole, a Globally Approved Triazole Antifungal Drug with Broad-spectrum Antifungal Activity;Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics;2024-05-31

5. Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure–response analysis in pediatrics;AIDS;2024-05-17